Publication:
Her-2 positivity rate in dogs with mammary carcinoma: A systematic review and meta-analysis

dc.contributor.buuauthorUzabacı, Ender
dc.contributor.buuauthorUZABACI, ENDER
dc.contributor.buuauthorÖzyiğit, Musa Özgür
dc.contributor.buuauthorÖZYİĞİT, MUSA ÖZGÜR
dc.contributor.buuauthorErcan, İlker
dc.contributor.buuauthorArda, O.
dc.contributor.departmentBursa Uludağ Üniversitesi/Veteriner Fakültesi/ Patoloji Anabilim Dalı.
dc.contributor.departmentBursa Uludağ Üniversitesi/Veteriner Fakültesi/ Biyoistatistik Anabilim Dalı.
dc.contributor.orcid0000-0002-9634-0055
dc.contributor.orcid0000-0002-2382-290X
dc.contributor.researcheridJPL-5273-2023
dc.contributor.researcheridABF-2367-2020
dc.contributor.researcheridAAR-6478-2021
dc.date.accessioned2024-07-04T12:54:13Z
dc.date.available2024-07-04T12:54:13Z
dc.date.issued2020-04-01
dc.description.abstractHuman epidermal growth factor receptor 2 (HER-2) plays an essential role in cell growth and survival. HER-2 overexpression occurs in 20-30% of human breast tumors and has prognostic value as it is associated with disease progression. HER-2 overexpression is also associated with tumor progression and metastasis in malignant mammary tumors of the canine. However, in the literature, different positivity classifications/scoring were used in the evaluation of HER-2 status, and there is no consensus in terms of scoring of HER-2 expression in canine mammary tumors. In this study, it was aimed to estimate the HER-2 positivity rate by evaluating the results of the study using different positivity classifications by meta-analysis. In this context, by using "HER-2 canine mammary tumor" keywords, Pubmed and Web of Science electronic databases were scanned until February 2019, and a total of 97 related studies were found. However, 20 of these studies were used for the analysis. Two different meta-analyses were performed to evaluate the HER-2 positivity status with "2+ and 3+" and "3+" scores. As a result, HER-2 positivity rates were determined at 25.87% and 25.99% for the studies using "2+/3+" scores and "3+" respectively for HER-2 positivity. Therefore, this result suggests that the rate of HER-2 positivity is similar between humans and dogs.
dc.identifier.endpage2148
dc.identifier.issn1792-2720
dc.identifier.issue2
dc.identifier.startpage2141
dc.identifier.urihttps://hdl.handle.net/11452/42919
dc.identifier.volume71
dc.identifier.wos000558376300008
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherHellenic Veterinary Medical Soc
dc.relation.journalJournal Of The Hellenic Veterinary Medical Society
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectHuman-breast
dc.subjectIn-situ
dc.subjectExpression
dc.subjectTumors
dc.subjectEgfr
dc.subjectOverexpression
dc.subjectPhenotype
dc.subjectOncogene
dc.subjectEstrogen
dc.subjectHer-2
dc.subjectMeta-analysis
dc.subjectCanine
dc.subjectMammary tumor
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectVeterinary sciences
dc.titleHer-2 positivity rate in dogs with mammary carcinoma: A systematic review and meta-analysis
dc.typeReview
dspace.entity.typePublication
relation.isAuthorOfPublication415edb5b-1ae0-491a-bd6a-97c2d1a6ec1e
relation.isAuthorOfPublication3a2cbbbb-163d-428a-9caa-27708d631560
relation.isAuthorOfPublication.latestForDiscovery415edb5b-1ae0-491a-bd6a-97c2d1a6ec1e

Files

Collections